person · Reporting owner
KUCHARCHUK ANDREW ALBERT
Disclosed activity across 7 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adhera Therapeutics, Inc.ATRX · Entity 127789 | Director · Chief Executive Officer | July 07, 2020 | July 20, 2020 |
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Chief Financial Officer | January 07, 2026 | January 09, 2026 |
| Chain Bridge ICBRG · Entity 9574 | Chief Financial Officer | April 01, 2024 | April 05, 2024 |
| RRE Ventures Acquisition Corp.RREV · Entity 5843 | Chief Financial Officer | April 29, 2026 | April 29, 2026 |
| Range Capital Acquisition Corp IIRNGTU · Entity 5882 | Chief Financial Officer | October 02, 2025 | October 02, 2025 |
| THERALINK TECHNOLOGIES, INC.OBMP · Entity 94673 | Director | June 05, 2020 | June 09, 2020 |
| WINDTREE THERAPEUTICS INC /DE/WINT · Entity 8761 | Director | August 03, 2025 | August 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adhera Therapeutics, Inc.
Report date July 07, 2020 · Filed July 20, 2020
This filing explicitly reported no securities owned.
CERO THERAPEUTICS HOLDINGS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-01-06 | Direct | 1,162,099 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 1,162,099 · Balance 1,162,099 |
Chain Bridge I
Report date April 01, 2024 · Filed April 05, 2024
This filing explicitly reported no securities owned.
RRE Ventures Acquisition Corp.
Report date April 29, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-29 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Range Capital Acquisition Corp II
Report date October 02, 2025 · Filed October 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-10-02 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B ordinary shares of Range Capital Acquisition Corp II (the "Issuer") have no expiration date and will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment, as described in the Registration Statement on Form S-1 (File No. 333-290118) (the "Registration Statement") related to the Issuer's initial public offering (the "IPO"). |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B ordinary shares of Range Capital Acquisition Corp II (the "Issuer") have no expiration date and will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment, as described in the Registration Statement on Form S-1 (File No. 333-290118) (the "Registration Statement") related to the Issuer's initial public offering (the "IPO").
THERALINK TECHNOLOGIES, INC.
Report date June 05, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series D-2 Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 241 |
Reported balance
After 2020-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-05 · Grant · Acquired 241 · Balance 241 F3: No additional consideration need be paid for the automatic conversion to common stock to take place. F1: The Series D-2 Convertible Preferred Stock will automatically convert into shares of Common Stock upon the filing of an amendment to the Issuer's Articles of Incorporation with the Secretary of State of the State of Nevada to increase the number of shares of Common Stock the Issuer is authorized to issue. F2: The Series D-2 Convertible Preferred has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series D-2 Convertible Preferred Stock will automatically convert into shares of Common Stock upon the filing of an amendment to the Issuer's Articles of Incorporation with the Secretary of State of the State of Nevada to increase the number of shares of Common Stock the Issuer is authorized to issue.
F2: The Series D-2 Convertible Preferred has no expiration date.
F3: No additional consideration need be paid for the automatic conversion to common stock to take place.
WINDTREE THERAPEUTICS INC /DE/
Report date August 03, 2025 · Filed August 05, 2025
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 21:30 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 1,162,099 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001213900-26-002948 · ownership.xml · derivative · entry 1 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,162,099 Underlying: Common Stock · 1,162,099 shares Expires 2036-01-06 Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:57 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 152,500 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001213900-25-050105 · ownership.xml · derivative · entry 1 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,500 Underlying: Common Stock · 152,500 shares Expires 2035-05-29 F1 · derivative.exercise_date: The shares underlying this option shall vest in equal monthly installments through June 4, 2027. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 23:03 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001213900-24-084759 · ownership.xml · derivative · entry 1 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-09-30 F1 · derivative.exercise_date: The shares underlying this option vest in twelve (12) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:33 UTC | THERALINK TECHNOLOGIES, INC. OBMP · Entity 94673 | GrantSeries D-2 Convertible Preferred Stock · Derivative | 241 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001493152-20-010889 · ownership.xml · derivative · entry 1 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241 Underlying: Common Stock · 2,410,000 shares Expires not disclosed F3 · price: No additional consideration need be paid for the automatic conversion to common stock to take place. F1 · derivative.exercise_date: The Series D-2 Convertible Preferred Stock will automatically convert into shares of Common Stock upon the filing of an amendment to the Issuer's Articles of Incorporation with the Secretary of State of the State of Nevada to increase the number of shares of Common Stock the Issuer is authorized to issue. F2 · derivative.expiration_date: The Series D-2 Convertible Preferred has no expiration date. Read SEC document |
| May 07, 2020 Filed May 8, 2020 17:17 UTC | THERALINK TECHNOLOGIES, INC. OBMP · Entity 94673 | GrantShares of Common Stock | 283,334 | $0.06 | $17,000.04 |
DisclosureSEC source: 0001493152-20-008105 · ownership.xml · nonDerivative · entry 1 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,001 F1 · price: The Issuer issued 283,334 shares to the Reporting Person in lieu of and in satisfaction of accrued and unpaid compensation of $17,000. Read SEC document |
| May 09, 2018 Filed May 11, 2018 18:15 UTC | THERALINK TECHNOLOGIES, INC. OBMP · Entity 94673 | GrantOption (right to buy) · Derivative | 3,000,000 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001493152-18-006688 · form4.xml · derivative · entry 1 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2028-05-09 F1 · price: Options issued as compensation approved by the Issuer's Board of Directors. Read SEC document |
| May 09, 2018 Filed Mar 14, 2019 17:50 UTC Amendment | THERALINK TECHNOLOGIES, INC. OBMP · Entity 94673 | GrantEmployee Stock Option (right to buy) · Derivative | 3,000,000 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001493152-19-003373 · ownership.xml · derivative · entry 1 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2028-05-09 F3 · price: Options issued as compensation approved by the Issuer's Board of Directors F1 · balance_after: This form is being amended because the original Form 4 aggregated the two grants listed above as the same class of options, when they are actually two separate classes. Read SEC document |
| March 10, 2017 Filed Apr 20, 2017 08:45 UTC | THERALINK TECHNOLOGIES, INC. OBMP · Entity 94673 | GrantEmplyee Stock Option (right to buy) · Derivative | 2,000,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001493152-17-004209 · form4.xml · derivative · entry 1 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2027-03-10 F1 · price: One-third of the Stock Options vest on March 10, 2018, March 10, 2019 and March 10, 2020. F1 · derivative.exercise_date: One-third of the Stock Options vest on March 10, 2018, March 10, 2019 and March 10, 2020. Read SEC document |
| March 10, 2017 Filed Mar 14, 2019 17:50 UTC Amendment | THERALINK TECHNOLOGIES, INC. OBMP · Entity 94673 | GrantEmployee Stock Option (right to buy) · Derivative | 2,000,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001493152-19-003373 · ownership.xml · derivative · entry 2 KUCHARCHUK ANDREW ALBERT · CIK 0001654127 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2027-03-10 F3 · price: Options issued as compensation approved by the Issuer's Board of Directors F2 · derivative.exercise_date: One-third of the Stock Options vested on March 10, 2018 and March 10, 2019 and one-third will vest on March 10, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.